Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, discusses results from the UK NCRI AML18 trial (NCT02272478) investigating a single versus fractionated schedule of gemtuzumab ozogamicin in combination with daunorubicin/cytarabine as induction therapy in older patients with acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).